{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:18Z","timestamp":1792048638040,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.semarthrit.2020.05.013","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T07:47:46Z","timestamp":1590824866000},"page":"744-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab \u2013 a real-world experience"],"prefix":"10.1016","volume":"50","author":[{"given":"Florence A.","family":"Aeschlimann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dumaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"W\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Melki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Uettwiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Job-Deslandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bader-Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.05.013_bib0001","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0002","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0003","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0004","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","article-title":"IL-6 blockade in the management of non-infectious uveitis","volume":"36","author":"Lopalco","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/rheumatology\/kex180","article-title":"Successful use of tocilizumab in two cases of severe autoinflammatory disease with a single copy of the Mediterranean fever gene","volume":"56","author":"Nikiphorou","year":"2017","journal-title":"Rheumatology"},{"issue":"Pt 1","key":"10.1016\/j.semarthrit.2020.05.013_bib0006","first-page":"481","article-title":"CEMARA an information system for rare diseases","volume":"160","author":"Landais","year":"2010","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0007","unstructured":"European Medicines Agency. ICH Topic E A: clinical safety data management: definitions and standards for expedited reporting: step 5 (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002749.pdf)."},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0008","doi-asserted-by":"crossref","unstructured":"Gr\u00f6nlund M.M., Remes-Pakarinen T., Kr\u00f6ger L., Markula-Patjas K., Backstr\u00f6m M., Putto-Laurila A., et al. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. Rheumatology2019 published on Jul 29. doi: 10.1093\/rheumatology\/kez291.","DOI":"10.1093\/rheumatology\/kez291"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0009","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jbspin.2018.08.003","article-title":"Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database","volume":"86","author":"Cabrera","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0010","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jbspin.2019.07.011","article-title":"Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte","volume":"87","author":"Dumaine","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0012","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpeds.2018.08.065","article-title":"Risk of serious infections associated with biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analyses","volume":"204","author":"Aeschlimann","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0013","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1084\/jem.20190344","article-title":"Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses","volume":"216","author":"Spencer","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0014","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1365-2133.2010.10005.x","article-title":"Onset of psoriasis following treatment with tocilizumab","volume":"163","author":"Laurent","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12969-020-0399-1","article-title":"Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"18","author":"Shimizu","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0016","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12969-019-0364-z","article-title":"Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial","volume":"17","author":"Mallalieu","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2020.05.013_bib0017","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3899\/jrheum.160072","article-title":"Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and\/or Uveitis: A Retrospective Longitudinal Cohort Study","volume":"44","author":"Aeschlimann","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722030144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722030144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:03:58Z","timestamp":1758733438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722030144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S004901722030144X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.05.013","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab \u2013 a real-world experience","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}